Inventiva S.A.

Inventiva S.A.

IVEVF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$869.99M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Inventiva S.A.Inventiva S.A.-6.4--947%-1.1
$-0.15

Current Fair Value

104.8% downside

Overvalued by 104.8% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$869.99 Million
Enterprise Value$770.57 Million
Earnings per Share$-1.9
Beta0.91
Outstanding Shares273,582,870

Return

Return on Equity-946.81%ROE
Return on Assets-222.38%
Return on Invested Capital-234.76%

Valuation & Multiples

P/E Ratio-6.4P/E Ratio
PEG10.67PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue71.41
Enterprise Value to EBIT-1.76
Enterprise Value to Net Income-2
Total Debt to Enterprise0.09
Debt to Equity1.13Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
September 28, 2026
EPS
-$0.29
Est. -$0.42
Revenue
$22,841
Est. $2.86 M

Next Earnings Call

Expected Date
March 31, 2027
EPS Estimate
-$0.32
Consensus analyst estimate
Revenue Estimate
$4.07 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Inventiva

77 employees
CEO: Frederic Cren

Inventiva S.A. is a clinical-stage biopharmaceutical firm dedicated to developing oral small molecule therapies. Its primary therapeutic focus areas include non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various o...